20923 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals Complement proteins, e.g. anaphylatoxin, C3a or C5a
COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
#2PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#3COMPOSITIONS AND METHODS FOR TREATING LUPUS NEPHRITIS
#4COMPLEMENT FACTOR I DOSING REGIMENS FOR TREATING OCULAR DISEASES
#5COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM INJURY
#6PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#7MULTIGENE CONSTRUCTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER COMPLEMENT DYSREGULATION-RELATED CONDITIONS
#8PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#9METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATOR
#10Compounds and compositions for intracellular delivery of therapeutic agents
#11COMBINATION THERAPY OF SOLID TUMORS USING CHIMERIC ANTIGEN RECEPTOR CELLS REPRESENTING ADAPTIVE AND INNATE IMMUNITY
#12METHODS OF TREATING, DIAGNOSING AND PREDICTING PROGNOSIS OF SEPSIS
#13METHODS FOR TREATING INFLAMMATORY OCULAR DISEASES WITH COMPLEMENT FACTOR H
#14FACTOR H FRAGMENT Fc FUSIONS WITH IMPROVED POTENCY AND MANUFACTURABILITY
#15Chimeric inhibitor molecules of complement activation
#16FACTOR B INHIBITORS AND USES THEREOF
#17METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH RECOMBINANT CFH PROTEINS
#18COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
#19METHODS FOR TREATING PATIENTS HAVING CFI MUTATIONS WITH RECOMBINANT CFI PROTEINS
#20C3 FUSION PROTEIN AND METHODS OF MAKING AND USING THEREOF
#21C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER
#22Autotransporter-mediated display of complement receptor ligands by bacterial immunogens
#23COMPOSITIONS AND METHODS RELATING TO C5L2
#24FUSION PROTEINS AND METHODS OF TREATING COMPLEMENT DYSREGULATION USING THE SAME
#25METHODS AND COMPOSITIONS TO INDUCE OR SUPPRESS IMMUNE RESPONSES THROUGH THE USE OF MEMBRANE BOUND COMPLEMENT SPLIT PRODUCTS
#26Compositions and methods for treating central nervous system injury
#27SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS
#28Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator
#29INHIBITION OF ALTERNATIVE COMPLEMENT PATHWAY FOR TREATMENT OF RETINAL ISCHEMIC INJURY AND GLAUCOMA
#30Composition for treating neuroinflammatory disease comprising complement component 8 gamma protein or fragment thereof
#31EXTRACTION PROCESS FROM COLOSTRUM
#32VCP and factor H as viral entry inhibitors
#33C3 fusion protein and methods of making and using thereof
#34COVERSIN FOR THE TREATMENT OF CICATRISING EYE INFLAMMATORY DISORDERS
#35COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF IMMUNE COMPLEX DISEASE
#36Fusion protein constructs comprising anti-C3d antibody and factor H
#37Chimeric inhibitor molecules of complement activation
#38Methods and compositions for treatment of Gaucher Disease via modulation of C5a receptor
#39Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide
#40HYDROCHLORIDE SALTS OF C5A RECEPTOR AGONIST PEPTIDES
#41Compounds and compositions for intracellular delivery of therapeutic agents
#42FACTOR H FRAGMENT FOR USE AS AN ANTI-ANGIOGENIC AGENT
#43Peptide compounds to regulate the complement system
#44C3A receptor agonists for use against ischemic brain injury, stroke, traumatic brain injury, spinal cord injury and neurodegenerative disorders
#45Compositions and methods for treating central nervous system injury
#46COMPOSITIONS AND METHODS RELATING TO C5L2
#47C3D cellular and acellular vaccines for the prevention and treatment of cancer
#48ANTI-ANTITHROMBIN SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF
#49Controlled-release peptide compositions and uses thereof
#50Compounds and compositions for intracellular delivery of therapeutic agents
#51Derivative Peptide Compounds and Methods of Use
#52Synthesis and structure of high potency RNA therapeutics
#53Modulators of complement function
#54Chimeric inhibitor molecules of complement activation
#55Compounds and compositions for intracellular delivery of therapeutic agents
#56Peptide compounds to regulate the complement system
#57METHODS AND COMPOSITIONS FOR TREATMENT OF GAUCHER DISEASE VIA MODULATION OF C5A RECEPTOR
#58Compounds and compositions for intracellular delivery of therapeutic agents
#59Stable liquid formulations of recombinant fusion proteins
#60Pure platelet-rich plasma (P-PRP) composition for treatment of subclinical mastitis and methods of producing and using the same
#61Compounds and compositions for intracellular delivery of therapeutic agents
#62Chimeric inhibitor molecules of complement activation
#63Derivative peptide compounds and methods of use
#64C1q as a therapeutic agent of allergy and/or asthma
#65Peptide compounds to regulate the complement system
#66Antibiotic composition comprising a chemotactic agent and a nutrient dispersion
#67COMPOSITIONS AND METHODS RELATING TO C5L2
#68Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
#69CONJUGATES AND SMALL MOLECULES WHICH INTERACT WITH THE CD16A RECEPTOR
#70Chimeric inhibitor molecules of complement activation
#71Peptide compounds to regulate the complement system
#72Antibiotic composition comprising a chemotactic agent and a nutrient dispersion
#73Factor H for treatment of rheumatoid arthritis
#74Adrenomedullin assays and methods for determining mature adrenomedullin
#75Controlled-release peptide compositions and uses thereof
#76Compositions and methods for immunomodulation
#77Proteomic IPF markers
#78Method for producing factor H from a plasma precipitation fraction
#79METHOD FOR TREATING ALS VIA THE INCREASED PRODUCTION OF FACTOR H
#80METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS
#81MODULATION OF EFFECTOR T CELL RESPONSES BY LOCAL DEPLETION OF COMPLEMENT COMPONENT C3
#82Manufacture of factor H (FH) and FH-derivatives from plasma
#83Chimeric inhibitor molecules of complement activation
#84Compositions and methods for treating bone conditions
#85Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen
#86Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
#87Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
#88Manufacture of factor H (FH) and FH-derivatives from plasma
#89Methods for treating multiorgan, systemic degos' disease with a complement inhibitor
#90METHOD OF INHIBITNG COMPLEMENT ACTIVATION WITH HUMAN ANTI-FACTOR C3 ANTIBODIES AND USE THEREOF
#91METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS
#92Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
#93COMPLEMENT PROTEINS
#94Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen
#95MODULATION AND REPLETION/ENHANCEMENT OF THE COMPLEMENT SYSTEM FOR TREATMENT OF TRAUMA
#96METHOD OF TREATING T CELL MEDIATED DISORDERS
#97Manufacture of factor H (FH) and FH-derivatives from plasma
#98Regulation of TLR Signaling by Complement
#99INHIBITING ACTIVATION WITH HUMAN ANTI-FACTOR C3 ANTIBODIES AND USE THEREOF
#100Methods and Compositions for Treating Ocular Disorders
#101Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
#102AGENT FOR PROMOTING OSTEOGENESIS AND/OR INHIBITING BONE RESORPTION
#103Vessel enlargement by arteriogenic factor delivery
#104Novel Antimicrobial Peptides
#105Agent for promoting osteogenesis and/or inhibiting bone resorption